HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

03692 HANSOH PHARMA

Not Yet Opened 02-04 16:08:25

36.880

-0.580

-1.55%

High37.760	Low36.480	Vol7.49M
Open37.660	D1 Closing37.460	Amplitude3.42%
Mkt Cap223.31B	Tradable Cap223.31B	Total Shares6.06B
T/O276.20M	T/O Rate0.12%	Tradable Shares6.06B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"HANSOH PHARMA","latestPrice":36.88,"timestamp":1770192505007,"preClose":37.46,"halted":0,"volume":7488396,"delay":0,"changeRate":-0.015483182060864877,"floatShares":6055000000,"shares":6055000000,"eps":0.8298040122498087,"marketStatus":"Not Yet Opened","change":-0.58,"latestTime":"02-04 16:08:25","open":37.66,"high":37.76,"low":36.48,"amount":276202748,"amplitude":0.03417,"askPrice":36.92,"askSize":38000,"bidPrice":36.86,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":0.9038365332104187,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":0,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":37.46,"dividendRate":0.009948,"openAndCloseTimeList":[[1770168600000,1770177600000],[1770181200000,1770192000000]],"volumeRatio":0.9775181922021632,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2608535621","title":"Hansoh Pharmaceutical Group  Stock Slips 1.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2608535621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608535621?lang=en_us&edition=fundamental","pubTime":"2026-02-04 16:33","pubTimestamp":1770193980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. shed 1.5% to 36.88 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 26847.32.Hansoh Pharmaceutical Group Co. Ltd. closed 17% short of its 52-week high of HK$44.22, which the company reached Jan. 15.Trading volume totaled 7.5 million shares, compared to the 50-day average of 8.5 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","03692","BK1583","BK1191"],"gpt_icon":0},{"id":"1109149685","title":"Hansoh Pharmaceutical (3692) Completes HK$4,680 Million Zero Coupon Convertible Bond Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=1109149685","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109149685?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:46","pubTimestamp":1770122785,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited (stock code: 3692) has announced the completion of its issuance of HK$4,680 million zero coupon convertible bonds due 2033, finalized on February 3, 2026....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"gpt_icon":0},{"id":"2608042873","title":"Hansoh Pharmaceutical Completes HK$4.68 Billion Zero Coupon Convertible Bond Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2608042873","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608042873?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:12","pubTimestamp":1770120724,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. has completed the issuance of HK$4,680 million zero coupon convertible bonds due 2033. The company announced that all conditions precedent to the issue, as set out in the subscription agreement, have been satisfied, and the bonds were successfully issued on February 3, 2026. The listing approval for the conversion shares has been obtained from the Hong Kong Stock Exchange, and the bonds are expected to be admitted to trading and listing on the Vienna MTF operated by the Vienna Stock Exchange.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong K","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL5KB0SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","BK1583","03692"],"gpt_icon":0},{"id":"1116348419","title":"Hansoh Pharmaceutical (03692) Announces January 2026 Monthly Return and Convertible Bonds Maturity","url":"https://stock-news.laohu8.com/highlight/detail?id=1116348419","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116348419?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:26","pubTimestamp":1770110818,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited (stock code: 03692) reported that its authorized share capital remained unchanged at 20,000,000,000 ordinary shares with a par value of HKD 0.00001 each,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"gpt_icon":0},{"id":"2608385996","title":"Hansoh Pharmaceutical Group  Stock Falls 3.2% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2608385996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608385996?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:32","pubTimestamp":1770021120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slipped 3.2% to 37.38 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 2.2% to 26775.57.Hansoh Pharmaceutical Group Co. Ltd. closed 15% short of its 52-week high of HK$44.22, which the company achieved Jan. 15.Trading volume totaled 8.1 million shares, compared to the 50-day average of 8.4 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","03692","BK1583"],"gpt_icon":0},{"id":"2607701112","title":"Hansoh Pharmaceutical Group  Stock Falls 1.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2607701112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607701112?lang=en_us&edition=fundamental","pubTime":"2026-01-29 16:33","pubTimestamp":1769675580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slid 1.4% to 38.50 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.5% to 27968.09.Hansoh Pharmaceutical Group Co. Ltd. closed 13% short of its 52-week high of HK$44.22, which the company reached Jan. 15.Trading volume totaled 6.3 million shares, compared to the 50-day average of 8.4 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","BK1191","03692"],"gpt_icon":0},{"id":"2606720164","title":"Hansoh Pharmaceutical Group  Stock Slips 4.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2606720164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606720164?lang=en_us&edition=fundamental","pubTime":"2026-01-27 16:30","pubTimestamp":1769502600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. shed 4.4% to 38.48 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 27126.95.Hansoh Pharmaceutical Group Co. Ltd. closed 13% short of its 52-week high of HK$44.22, which the company achieved Jan. 15.Trading volume totaled 10.9 million shares, compared to the 50-day average of 8.3 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2606246278","title":"BRIEF-Hansoh Pharmaceutical Issue Of Hk$4,680 Million Zero Coupon Convertible Bonds Due 2033","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246278","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606246278?lang=en_us&edition=fundamental","pubTime":"2026-01-27 09:17","pubTimestamp":1769476670,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical Issue Of Hk$4,680 Million Zero Coupon Convertible Bonds Due 2033Jan 27  - Hansoh Pharmaceutical 3692.HK:PROPOSED ISSUE OF HK$4,680 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2033BONDS CONVERTIBLE INTO 81.5 MILLION SHARES AT HK$57.39 PER SHAREFurther company coverage: 3692.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nFWN3YR0QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1583","BK1191"],"gpt_icon":0},{"id":"1131949532","title":"HANSOH PHARMA (03692) Proposes Issuance of HK$4.68 Billion Zero-Coupon Convertible Bonds Due 2033","url":"https://stock-news.laohu8.com/highlight/detail?id=1131949532","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131949532?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:48","pubTimestamp":1769467700,"startTime":"0","endTime":"0","summary":"On January 26, 2026 (after trading hours), HANSOH PHARMA (03692) announced that the company entered into a subscription agreement with the placing agents. Under the terms of the subscription...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","03692","BK1589"],"gpt_icon":0},{"id":"2606049229","title":"Hansoh Pharmaceutical - Proposed Issue of HK$4,680 Mln Zero Coupon Convertible Bonds Due 2033","url":"https://stock-news.laohu8.com/highlight/detail?id=2606049229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606049229?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:02","pubTimestamp":1769464976,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1589","03692","BK1583"],"gpt_icon":0},{"id":"2605451453","title":"Does Hansoh Pharmaceutical Group's (SEHK:3692) Ameile Label Expansion Reveal a Deeper Oncology Strategy Shift?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605451453","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605451453?lang=en_us&edition=fundamental","pubTime":"2026-01-22 09:39","pubTimestamp":1769045979,"startTime":"0","endTime":"0","summary":"Earlier this month, Hansoh Pharmaceutical Group announced that China’s National Medical Products Administration approved an additional indication for its innovative lung cancer drug Ameile, allowing its use with pemetrexed and platinum-based chemotherapy as a first-line treatment for certain adult EGFR-mutated NSCLC patients, marking the drug’s fifth approved indication.\nThis latest approval meaningfully broadens Ameile’s clinical footprint in lung cancer, underscoring Hansoh’s focus on...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/does-hansoh-pharmaceutical-groups-sehk3692-ameile-label-expa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/does-hansoh-pharmaceutical-groups-sehk3692-ameile-label-expa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1589","BK1191","03692","BK1583"],"gpt_icon":0},{"id":"2604018916","title":"Hansoh Pharmaceutical Group  Stock Sheds 4.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2604018916","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604018916?lang=en_us&edition=fundamental","pubTime":"2026-01-19 16:30","pubTimestamp":1768811400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slid 4.0% to 41.28 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 26563.90.This was the stock's second consecutive day of losses.Hansoh Pharmaceutical Group Co. Ltd. closed 6.6% below its 52-week high of HK$44.22, which the company achieved Jan. 15.Trading volume totaled 6.0 million shares, compared to the 50-day average of 8.5 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","BK1583","03692"],"gpt_icon":0},{"id":"2603695625","title":"Hansoh Pharmaceutical Group  Stock Rallies 2.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2603695625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603695625?lang=en_us&edition=fundamental","pubTime":"2026-01-14 16:32","pubTimestamp":1768379520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. rose 2.1% to 42.94 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.6% to 26999.81.This was the stock's second consecutive day of gains.Hansoh Pharmaceutical Group Co. Ltd. closed 2.9% short of its 52-week high of HK$44.22, which the company achieved Dec. 12.Trading volume totaled 10.2 million shares, compared to the 50-day average of 8.7 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"1190906700","title":"HK Stock Movement | HANSOH PHARMA (03692) Rises Over 4% Before Noon; Ameile® Gains Fifth Indication Approval; Adjuvant Therapy Research Published in The Lancet Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1190906700","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190906700?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:45","pubTimestamp":1768275940,"startTime":"0","endTime":"0","summary":"HANSOH PHARMA (03692) rose more than 4% before noon. As of the time of writing, the stock was up 3.64%, trading at HK$42.12 with a turnover of HK$97.6223 million. On January 8, HANSOH PHARMA...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1583","BK1191"],"gpt_icon":0},{"id":"2602976005","title":"China Approves Ameile Combination Therapy as First-Line Treatment for EGFR-Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2602976005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602976005?lang=en_us&edition=fundamental","pubTime":"2026-01-12 16:44","pubTimestamp":1768207442,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co., Ltd. announced that its drug Ameile  has received regulatory approval in China for a new indication. The newly approved use is Ameile in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer  whose tumors have EGFR exon 19 deletions or exon 21  mutations. This approval is supported by results from the Phase III AENEAS 2 study, which demonstrated a significant improvement in progression-free survival and objective response rate compared to monotherapy, with no new safety concerns. This marks the fifth approved indication for Ameile in China, enabling full-course treatment coverage for EGFR-mutated NSCLC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7BBC05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1583","BK1589"],"gpt_icon":0},{"id":"2602711592","title":"Hansoh Pharmaceutical Group  Stock Sheds 2.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2602711592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602711592?lang=en_us&edition=fundamental","pubTime":"2026-01-12 16:32","pubTimestamp":1768206720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. shed 2.3% to 40.64 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 26608.48.The stock's fall snapped a six-day winning streak.Hansoh Pharmaceutical Group Co. Ltd. closed 8.1% below its 52-week high of HK$44.22, which the company reached Dec. 12.Trading volume totaled 7.3 million shares, compared to the 50-day average of 8.8 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","03692","BK1583"],"gpt_icon":0},{"id":"2602853876","title":"Hansoh Pharmaceutical Group SEHK 3692 Valuation Check After Ameile First Line Lung Cancer Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2602853876","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602853876?lang=en_us&edition=fundamental","pubTime":"2026-01-10 17:31","pubTimestamp":1768037496,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group (SEHK:3692) has just received Chinese NMPA approval to expand lung cancer drug Ameile’s use as a first line option in combination therapy for specific EGFR mutated NSCLC patients.\nSee our latest analysis for Hansoh Pharmaceutical Group.\nThe Ameile update comes after a reshuffle of Hansoh Pharmaceutical Group’s board and committees in late December 2025. The latest 1-day share price return of 2.11% at HK$41.6 sits within a year-to-date share price return of 14.16%...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk-3692-valuation-check-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk-3692-valuation-check-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1583","BK1191","03692","BK1589"],"gpt_icon":0},{"id":"2601369315","title":"Hansoh Pharma Gets China Nod for Additional Indication of Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369315","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369315?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:11","pubTimestamp":1767874289,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group  said an additional indication of Ameile was granted registration approval by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The additional indication is for use of the drug in combination with pemetrexed and platinum-based chemotherapy to treat adult patients with locally advanced or metastatic non-small cell lung cancer.This is the fifth indication of the drug which has been approved.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1589","BK1191","03692"],"gpt_icon":0},{"id":"1191152049","title":"HANSOH PHARMA (03692): Ameile® (Almonertinib Mesylate Tablets) Receives Fifth Indication Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1191152049","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191152049?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:50","pubTimestamp":1767865839,"startTime":"0","endTime":"0","summary":"HANSOH PHARMA (03692) announced that its innovative drug Ameile® (Almonertinib Mesylate Tablets) has obtained a drug registration certificate issued by China's National Medical Products...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","03692","BK1191"],"gpt_icon":0},{"id":"2601357483","title":"Hansoh Pharmaceutical Wins NMPA Approval for Fifth Ameile Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2601357483","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601357483?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:47","pubTimestamp":1767865664,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. has announced that its innovative drug Ameile  has received drug registration approval from the National Medical Products Administration  of China for a fifth indication. The new approval allows Ameile, in combination with pemetrexed and platinum-based chemotherapy, to be used as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer  whose tumors have EGFR exon 19 deletions or exon 21  mutations. This regulatory milestone expands the therapeutic options for NSCLC patients with specific EGFR mutations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL174lT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","BK1191","03692"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0558},{"period":"1month","weight":-0.0315},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0493},{"period":"1year","weight":1.0159},{"period":"ytd","weight":0.0222}],"compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0136},{"period":"6month","weight":0.08},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002565},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.005714},{"month":3,"riseRate":0.333333,"avgChangeRate":0.024785},{"month":4,"riseRate":0.5,"avgChangeRate":0.03201},{"month":5,"riseRate":0.666667,"avgChangeRate":0.019349},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055622},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000332},{"month":8,"riseRate":0.714286,"avgChangeRate":0.01897},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033021},{"month":10,"riseRate":0.142857,"avgChangeRate":0.001586},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063467},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016858}],"exchange":"SEHK","name":"HANSOH PHARMA","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HANSOH PHARMA(03692) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HANSOH PHARMA,03692,HANSOH PHARMA股票,HANSOH PHARMA股票老虎,HANSOH PHARMA股票老虎国际,HANSOH PHARMA行情,HANSOH PHARMA股票行情,HANSOH PHARMA股价,HANSOH PHARMA股市,HANSOH PHARMA股票价格,HANSOH PHARMA股票交易,HANSOH PHARMA股票购买,HANSOH PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HANSOH PHARMA(03692) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}